The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N06 | Psychoanaleptics | |
3
|
N06D | Anti-dementia drugs | |
4
|
N06DX | Other anti-dementia drugs | |
5
|
N06DX05 |
| Active Ingredient |
|---|
|
Donanemab is an immunoglobulin gamma 1 (IgG1) monoclonal antibody with high affinity for a modified, N-terminal truncated form of amyloid beta (N3pE Aβ). N3pE Aβ is present in brain amyloid plaques at low levels, and not detected in plasma and CSF. Donanemab binds to N3pE Aβ and aids plaque removal through microglial-mediated phagocytosis. |
| Document | Type | Information Source | |
|---|---|---|---|
| KISUNLA Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| KISUNLA Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.